The benefits of microsurgical approaches in periodontal therapy have been described. The main focus of this study is to determine if using microsurgical LMCAF technique would improve the outcomes of the therapy for the Miller Class III isolated recession-type defects.

Six months results of this study showed that LMCAF with microsurgical approach offered better complete and mean root coverage results over macrosurgical LMCAF technique. The superior effect of microsurgical approach on post-operative morbidity can make this technique more preferable for the patients who expected comfortable postoperative period.

This study supports that using the microsurgical aproach with LMCAF procedure significantly affects the clinical and patient-centered success of treating Miller Class III isolated typed defects.

Inclusion Criteria:

• Presence of Miller Class III isolated gingival recessions located at upper and lower incisors and canines (Miller 1985)
• Presence of identifiable cementoenamel junction (CEJ)
• Presence of a step ≤ 2mm at CEJ level and/or the presence of a root abrasion, but with an identifiable CEJ
• Lateral keratinized tissue width at least 6 mm greater than the width of the recession measured at the level of the cemento-enamel junction (CEJ)
• Lateral keratinized tissue height at least 2 mm greater than the buccal probing depth of the adjacent tooth/teeth
• Full-mouth plaque score and full-mouth bleeding score of < 15% (four sites/tooth) -No occlusal interferences; all patients were nonsmokers

Exclusion Criteria:

• Tooth with a prosthetic crown or restoration involving CEJ
• Patients with a history of destructive periodontal disease (o zaman class 3 nasıl oluştu demiş adam) or repeated abscess formation
• Presence of systemic disease or taking medications known to interfere with periodontal tissue health or healing (patients with insulin-dependent diabetes
• History of malignancy, radiotherapy, or chemotherapy for malignancy
• Disease affecting connective tissue metabolism)
• Patient pregnant or nursing during the past 5 months
• Patients who participated in a clinical trial within the past 6 months